Panacea Venture

VelaVigo is a biopharmaceutical company focused on developing innovative macromolecular drugs. It aims to create an efficient drug discovery pipeline backed by robust translational medicine capabilities, with the goal of providing affordable and differentiated high-quality new biological drugs for patients.

Founded in 2013, Human Longevity is a genomic-based health intelligence company headquartered in San Diego, California. It combines the largest database of genomic and phenotypic data with machine learning to drive discoveries and empower proactive healthcare. The company's core offerings include the HLI Health Nucleus, which uses whole-genome sequence analysis and advanced clinical imaging to deliver comprehensive personal health insights.

CASI Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company dedicated to developing and commercializing innovative therapeutics, particularly in the fields of hematology and oncology. The company focuses on addressing unmet medical needs by acquiring and launching products in China, the United States, and globally. CASI's product portfolio includes several therapeutics, such as EVOMELA, which is used as a conditioning treatment prior to autologous stem cell transplants for multiple myeloma patients, along with CID-103, CNCT19, MARQIBO, ZEVALIN, and ENMD-2076. The company's primary revenue driver is the sales of EVOMELA, as it executes its strategy to become a leading biopharmaceutical player by leveraging its expertise in regulatory and commercial operations within the China market.

Established in 2022, Eos BioInnovation is a venture capital firm headquartered in Cambridge, Massachusetts. It focuses on investing in science and technology sectors.

Actym Therapeutics is a biotechnology company based in Berkeley, California. Founded in 2017, the company specializes in the discovery and development of novel immuno-oncology therapies to treat cancer. Actym's proprietary platform, STACT, uses attenuated bacteria to deliver multiplexed immunomodulatory payloads directly to tumor-resident immune cells, targeting intractable pathways with minimal systemic toxicities.

Chime Biologics Limited is a Contract Development and Manufacturing Organization (CDMO) based in Wuhan, China, specializing in biopharmaceutical development and manufacturing services. Established in 2013, the company offers a wide range of services, including drug substance and drug product manufacturing, cell line development, and protein science characterization. It also supports clients with technical transfer, regulatory guidance, and project management to ensure a comprehensive solution throughout the biopharmaceutical development lifecycle. Chime Biologics focuses on delivering customer-centric, cost-effective, high-quality services that cater to the evolving needs of the biopharmaceutical industry, facilitating early-stage development through late-stage clinical research and commercial production.

Base Therapeutics is focused on developing innovative cell and gene editing technologies to address cancerous diseases. The company has created a natural killer cell genetic engineering platform, along with various cell therapy products aimed at treating several types of cancer, including lung cancer, liver cancer, glioma, and other hematological tumors. Through its advanced technologies, Base Therapeutics aims to enhance the safety and effectiveness of clinical applications of gene editing, both in vivo and in vitro, providing healthcare professionals with improved treatment options for patients suffering from these serious conditions.

NewAmsterdam Pharma is a clinical-stage biopharmaceutical company focused on researching and developing transformative therapies for cardio-metabolic diseases. Founded in 2019 and based in Naarden, the Netherlands, it is developing obicetrapib, an oral, low-dose CETP inhibitor intended to lower LDL-C and potentially address statin intolerance or residual risk in patients with ASCVD or familial hypercholesterolemia on maximally tolerated statin therapy. The company aims to improve patient care in populations where approved therapies are inadequate or poorly tolerated.

Founded in 2017, Coastar Therapeutics specializes in developing a proprietary erythrocyte enveloped virus delivery technology platform. This platform enables repeated virus dosing by evading immune system recognition and attack, addressing challenges in systemic drug therapies. Coastar's process technology focuses on red blood cell membranes, facilitating mass production and standardization with cost advantages. The company's initial product targets oncolytic viruses.

Jade Biomedical is a pioneering organization that specializes in regulatory and analytical testing services for biopharmaceutical companies globally. Recognized as the world's first registered biologics contract organization, Bio-CQOR, Jade Biomedical offers comprehensive quality management solutions tailored to the biopharmaceutical sector. The company provides a range of services, including contract quality, GMP testing, technical contracting, and inspection solutions. Its leadership team possesses extensive experience with major drug regulatory agencies such as NMPA, FDA, EMA, PMDA, and PICS, ensuring a deep understanding of the regulatory landscape. Jade Biomedical's expertise spans various therapeutic platforms, including monoclonal antibodies, antibody-drug conjugates, and advanced cell and gene therapies.

HanchorBio is a biotechnology research firm focused on developing innovative drugs for cancer treatment. The company specializes in drug discovery based on tumor immunology, with the goal of enhancing the quality of life for cancer patients. Through its research and development efforts, HanchorBio aims to revolutionize existing treatment paradigms and provide effective therapeutic options for those affected by cancer.

Fanen Biotechnology develops and manufactures tumor immunotherapy drugs, offering personalized CAR-T and TCR-T cell therapies, tumor vaccines, and immune checkpoint inhibitors. The company pairs its therapeutic offerings with proprietary diagnostics and GMP-grade production capabilities to help hospitals and cancer treatment centers access tailored immunotherapies, enabling precise and efficient treatment of solid tumors.

Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, focused on the discovery and early development of therapeutic drugs targeting G protein-coupled receptors (GPCRs), which are key drug targets in various diseases. Founded in 2001, the company specializes in developing small molecules for the treatment of central nervous system (CNS) disorders and cancer. It employs its proprietary technology platform, DTect-All, which enables the identification of orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs) that are challenging to discover using conventional methods. In addition, Domain Therapeutics offers BioSens-All, a platform to explore the signaling complexities associated with GPCR activation, enhancing its ability to address difficult targets, such as orphan and peptidic GPCRs.

GT Apeiron Therapeutics is a developer of innovative drugs utilizing artificial intelligence technology. The company develops breakthrough investigational medicines by harnessing the power of artificial intelligence, aiming to drastically increase efficiency throughout the drug discovery process.

Harvest Integrated Research Organization (HiRO) is an innovative clinical research organization (CRO) with a global presence. It offers a comprehensive suite of services tailored for biotechnology and pharmaceutical companies, including pre-clinical strategic planning, clinical trial design, regulatory affairs, pharmacovigilance, statistics, data management, and end-to-end project management. HiRO is committed to facilitating the transition of pharmaceutical products from the laboratory to the market, collaborating closely with its clients to develop more effective and cost-efficient therapies for patients worldwide. As an emerging leader in the CRO sector, HiRO aims to enhance the drug development process through its integrated capabilities and dedication to quality.

Day Zero Diagnostics develops sequencing-based diagnostics for infectious diseases. Its proprietary technologies enable rapid identification of bacterial species and antibiotic resistance profiles from clinical samples, targeting bloodstream infections and sepsis initially. The company aims to improve patient outcomes by providing comprehensive diagnoses within hours instead of days.

Yizun Biotechnology is a cutting-edge immune cell therapy company that has developed many unique platform technologies, including solid tumor treatment and allogeneic universal cell therapy.

TaiLai Biosciences is a biotechnology company based in Shanghai, China, focused on advancing cancer research through innovative multiomics technology. The company specializes in the development of non-invasive cancer screening and analysis tools, which allow researchers to gain deeper insights into cancer development and facilitate the creation of immune-guided therapies. TaiLai Biosciences offers a range of biopsy products and services that leverage proprietary biomultiomics technology, integrating extensive biological data, including DNA, RNA, proteins, and metabolites. By employing bioinformatics and computational science, the company aims to uncover correlations within this vast information, contributing to improved cancer diagnostics and treatment options.

VelaVigo is a biopharmaceutical company focused on developing innovative macromolecular drugs. It aims to create an efficient drug discovery pipeline backed by robust translational medicine capabilities, with the goal of providing affordable and differentiated high-quality new biological drugs for patients.

TriArm Therapeutics is a cell therapy company that specializes in developing cellular immunotherapy products aimed at treating cancer patients. It was established by Panacea Venture and conducts research and development operations across Germany, the United States, and the Greater China region. The company's primary focus is on the research and clinical application of its CD19 CAR-T product, utilizing non-viral gene transfer technology. This innovative approach significantly lowers the costs and reduces the time required for preparing cell therapy products, ultimately enhancing the effectiveness of tumor treatments.

Inmagene Biopharmaceuticals Co. Ltd. is a Shanghai-based biopharmaceutical company founded in 2019, specializing in the research and pre-clinical development of therapies for immunology-related diseases. The company focuses on creating innovative drug candidates that address unmet medical needs globally, employing a strategy known as "Borderless Innovation." Inmagene has developed a diverse pipeline, including IMG-020, a protein drug designed to target IL-17A, which utilizes a combination of Affibody's protein therapeutics platform and Albumod technology to enhance potency and extend half-life. In addition to IMG-020, the company boasts several clinical-stage assets and multiple preclinical candidates aimed at improving pharmacokinetic and pharmacodynamic properties, safety profiles, and dosing convenience for patients. With additional offices in Hangzhou and Beijing, Inmagene is dedicated to advancing drug development through cutting-edge technology and a commitment to global collaboration in the fight against immunological diseases.

Chime Biologics Limited is a Contract Development and Manufacturing Organization (CDMO) based in Wuhan, China, specializing in biopharmaceutical development and manufacturing services. Established in 2013, the company offers a wide range of services, including drug substance and drug product manufacturing, cell line development, and protein science characterization. It also supports clients with technical transfer, regulatory guidance, and project management to ensure a comprehensive solution throughout the biopharmaceutical development lifecycle. Chime Biologics focuses on delivering customer-centric, cost-effective, high-quality services that cater to the evolving needs of the biopharmaceutical industry, facilitating early-stage development through late-stage clinical research and commercial production.

Maestro Surgical is a technology company specializing in medical surgical robotics. It develops advanced motion control technology chipsets, designed to deliver real-time performance, synchronization, and miniaturization. The company's platform integrates proprietary medical image processing algorithms, facilitating efficient collection and utilization of X-ray data in the medical sector.

Innovative Rehabilitation Equipment Company that Helps Mobility-Impaired Patients to Regain Walking Ability

Inmagene Biopharmaceuticals Co. Ltd. is a Shanghai-based biopharmaceutical company founded in 2019, specializing in the research and pre-clinical development of therapies for immunology-related diseases. The company focuses on creating innovative drug candidates that address unmet medical needs globally, employing a strategy known as "Borderless Innovation." Inmagene has developed a diverse pipeline, including IMG-020, a protein drug designed to target IL-17A, which utilizes a combination of Affibody's protein therapeutics platform and Albumod technology to enhance potency and extend half-life. In addition to IMG-020, the company boasts several clinical-stage assets and multiple preclinical candidates aimed at improving pharmacokinetic and pharmacodynamic properties, safety profiles, and dosing convenience for patients. With additional offices in Hangzhou and Beijing, Inmagene is dedicated to advancing drug development through cutting-edge technology and a commitment to global collaboration in the fight against immunological diseases.

Zhaoke Ophthalmology Pharmaceutical is a Pharmaceutical platform.

XW Laboratories Inc. is a biopharmaceutical company based in Wuhan, China, specializing in the development of innovative treatments for neurological disorders. Founded in 2014, the company has established three distinct research and development platforms, including Prodrug and Functional Group Switch, which facilitate the rapid identification of novel drug candidates while minimizing development costs and time. The company is committed to creating medications that enhance patient compliance and reduce toxicity. Additionally, XW Laboratories is advancing its capabilities in immunoneurology through a mitochondria-targeting platform. While primarily focused on the Chinese market, the company also engages in collaborations to reach foreign markets, aiming to transform the quality of life for patients suffering from neurological conditions.

XWPharma is a neuroscience-focused biotech company developing novel therapeutics for sleep disorders, neuropsychiatric conditions, and other underserved central nervous system illnesses. The company emphasizes drug discovery and vaccine development to treat insomnia and related sleep disturbances, aiming to improve patient health and quality of life. Based in the Bay Area, California, XWPharma pursues innovative research to advance treatments for central nervous system disorders.

Actym Therapeutics is a biotechnology company based in Berkeley, California. Founded in 2017, the company specializes in the discovery and development of novel immuno-oncology therapies to treat cancer. Actym's proprietary platform, STACT, uses attenuated bacteria to deliver multiplexed immunomodulatory payloads directly to tumor-resident immune cells, targeting intractable pathways with minimal systemic toxicities.

Founded in 2013, Human Longevity is a genomic-based health intelligence company headquartered in San Diego, California. It combines the largest database of genomic and phenotypic data with machine learning to drive discoveries and empower proactive healthcare. The company's core offerings include the HLI Health Nucleus, which uses whole-genome sequence analysis and advanced clinical imaging to deliver comprehensive personal health insights.

TriArm Therapeutics is a cell therapy company that specializes in developing cellular immunotherapy products aimed at treating cancer patients. It was established by Panacea Venture and conducts research and development operations across Germany, the United States, and the Greater China region. The company's primary focus is on the research and clinical application of its CD19 CAR-T product, utilizing non-viral gene transfer technology. This innovative approach significantly lowers the costs and reduces the time required for preparing cell therapy products, ultimately enhancing the effectiveness of tumor treatments.

Juventas is a developer of innovative immune cell therapeutic drugs aimed at treating malignant hematological neoplasms, including leukemia and lymphoma. The company has had its first investigational new drug application for the cell therapeutic product CNCT19 accepted by the National Medical Products Administration. Juventas is committed to developing a comprehensive product pipeline that focuses on advancing immune cell therapies and accelerating innovation in this field, thereby providing effective treatment options for patients suffering from these serious conditions.

OncXerna Therapeutics, Inc. is a biotechnology company focused on developing precision medicines for cancer patients by utilizing an RNA-based biomarker platform. The company aims to improve patient outcomes by prospectively identifying individuals based on the unique RNA biology of their tumor microenvironments. This innovative approach enables OncXerna to match patients with targeted oncology therapies that correspond to their specific tumor characteristics. Founded in 2018 and based in Waltham, Massachusetts, with an additional location in Shanghai, China, OncXerna was formerly known as Oncologie, Inc. and changed its name in September 2020 to reflect its commitment to advancing next-generation precision medicine for a broader range of cancer patients.

Founded in 2016, Tactiva Therapeutics specializes in cancer immunotherapy. It focuses on adoptive cell therapy using anti-tumor CD8 T cells and helper CD4 T cells for potent cancer treatment.

Evox Therapeutics Limited is a biotechnology company based in Oxford, United Kingdom, that specializes in developing exosome-based therapeutics for the treatment of severe diseases with limited treatment options. Founded in 2016, the company focuses on harnessing and engineering extracellular vesicles, known as exosomes, to facilitate targeted delivery of nucleic acids and proteins. Evox's innovative platform allows for the modification of exosomes using advanced molecular engineering techniques, enabling effective drug delivery to specific organs, including the brain and central nervous system. By leveraging these natural delivery capabilities, Evox aims to overcome the limitations associated with conventional protein, antibody, and nucleic acid therapies, thereby creating novel therapeutic solutions that could significantly impact human health. The company is supported by a robust intellectual property portfolio and is positioned as a leader in this emerging therapeutic space.

BioGraph 55 is an immuno-oncology target discovery and drug development company focused on creating novel therapies for cancer and immune-related diseases. It develops B-cell–targeted therapies and bispecific antibodies for immuno-oncology and autoimmunity, employing a reverse translational approach to identify cellular targets within diseased tissues and validate mechanisms that drive disease. The company aims to address significant unmet clinical needs by leveraging insights from the tumor microenvironment to guide therapy development and translational science.

Atara Biotherapeutics, Inc. is a biotechnology company focused on developing off-the-shelf T-cell immunotherapies for patients with cancer, autoimmune diseases, and viral infections. The company is advancing tabelecleucel, a T-cell immunotherapy currently in Phase III clinical trials for treating Epstein-Barr virus-associated post-transplant lymphoproliferative disorder, as well as other related hematologic and solid tumors, including nasopharyngeal carcinoma. Atara is also working on next-generation CAR T immunotherapies targeting various indications, including ATA2271 and ATA3271 for mesothelin, and ATA2431 and ATA3219 for B-cell lymphomas. Additionally, its pipeline includes ATA188 for multiple sclerosis and several other candidates for conditions such as acute myeloid leukemia and cytomegalovirus. Founded in 2012, Atara Biotherapeutics is headquartered in South San Francisco, California, and collaborates with leading academic institutions to enhance its research and development efforts.